In a bid to streamline viral vector manufacturing, Thermo Fisher is charting another round of layoffs this year—and ...

Doctors have been fairly quick to jump on the biologics train: According to Spherix, 96% of dermatologists reported using ...

Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin ...

Watch out, Gilead and Novartis: there's a new CAR-T in town. Autolus is ready to hit the ground running after winning FDA approval for its Aucatzyl, a late entry to the heated CD19 CAR-T cell therapy ...

Amid a U.S. probe into its ties to the Chinese Communist Party (CCP), GenScript has revealed that it is setting up shop in Australia, with a new operations and logistics center designed to support the ...

Although ARS Pharmaceuticals’ approval for its epinephrine nasal spray came later than expected, the company ultimately received a thumbs up from the FDA in August and is now moving fast to expand ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

With Indivior’s stock price in freefall over the past year, one of the company’s top investors is taking leadership to task, ...